News | January 27, 2022
Moderna working on Omicron-specific booster candidate
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
UCB plans to submit regulatory applications in Q3 2022
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
Subscribe To Our Newsletter & Stay Updated
